By Stephen Nakrosis Shares of Relmada Therapeutics hit a 52-week high following news its chief executive and other executives recently purchased shares of.
Parsons Capital Management Inc. RI increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 11.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 974,082 shares of the company’s stock after purchasing an additional 100,770 shares during the quarter. Parsons […]
Relmada Therapeutics (RLMD) Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated
Relmada s Strong Balance Sheet to Support the Company Through All of 2024 s Expected Critical.